“It’s also important to note that Arlow’s company is doing synthesis as a service rather than selling bioprinters that can enable any researcher to make their own DNA.
‘One of the reasons we’re developing our business as a DNA synthesis service… as opposed to making a printer… is because that gives us a much greater ability to vet orders for biosecurity risk before we manufacture them,’ Arlow said.”
Read the full article.